Love Sandy
Division of Equine Clinical Studies, Faculty of Veterinary Medicine, University of Glasgow, Bearsden Road, Glasgow, Scotland G61 8QH, UK.
Vet Clin North Am Equine Pract. 2003 Dec;19(3):791-806. doi: 10.1016/j.cveq.2003.08.003.
Since 1917, only 11 new endoparasiticides have been developed for the horse, of which five chemical classes are in common use. The selection pressure of frequent administration of deworming doses for parasite control programs has been associated with the development of resistance of small strongyle parasites to the effects of benzimidazoles and pyrantel salts. Against the background of the inevitability of the occurrence of ivermectin/moxidectin resistance, responsible use of equine anthelmintics based on the clinical pharmacology of the compounds and the biology/epidemiology of intestinal parasites is a major issue for equine clinicians. The evidence base for the recommendations for treatment and control of equine intestinal parasites is sparse, however, and few robust data exist from controlled clinical trials to validate current guidelines.
自1917年以来，仅为马匹开发了11种新型体内寄生虫杀虫剂，其中有五类化学类别在普遍使用。在寄生虫控制计划中频繁给予驱虫剂量的选择压力，已与小型圆线虫寄生虫对苯并咪唑和噻嘧啶盐类产生耐药性有关。在伊维菌素/莫昔克丁耐药性不可避免出现的背景下，基于化合物的临床药理学以及肠道寄生虫的生物学/流行病学，合理使用马用驱虫药是马科临床医生面临的一个主要问题。然而，关于马肠道寄生虫治疗和控制建议的证据基础较为薄弱，并且来自对照临床试验的有力数据很少，难以验证当前的指南。
